RVMD Stock Overview
A clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Revolution Medicines, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$56.75 |
| 52 Week High | US$62.40 |
| 52 Week Low | US$20.98 |
| Beta | 1.4 |
| 11 Month Change | 16.99% |
| 3 Month Change | 30.04% |
| 1 Year Change | 162.98% |
| 33 Year Change | 110.03% |
| 5 Year Change | n/a |
| Change since IPO | 96.37% |
Recent News & Updates
Recent updates
Calculating The Intrinsic Value Of Revolution Medicines, Inc. (NASDAQ:RVMD)
Sep 28
This Is Why Revolution Medicines, Inc.'s (NASDAQ:RVMD) CEO Compensation Looks Appropriate
Jun 15Revolution Medicines: On Hold Pending A Lower Entry Point
Jun 04Revolution Medicines: An Expensive Shot At A Massive Market Opportunity
Apr 12Revolution Medicines Is Hard To Understand
Feb 01Here's Why We're Not Too Worried About Revolution Medicines' (NASDAQ:RVMD) Cash Burn Situation
Aug 09Some Analysts Just Cut Their Revolution Medicines, Inc. (NASDAQ:RVMD) Estimates
May 13We Think Revolution Medicines (NASDAQ:RVMD) Can Afford To Drive Business Growth
Apr 02We're Hopeful That Revolution Medicines (NASDAQ:RVMD) Will Use Its Cash Wisely
Dec 20We're Not Very Worried About Revolution Medicines' (NASDAQ:RVMD) Cash Burn Rate
Sep 15Revolution Medicines promotes Jack Anders to CFO
Sep 02New Forecasts: Here's What Analysts Think The Future Holds For Revolution Medicines, Inc. (NASDAQ:RVMD)
Aug 10Shareholder Returns
| RVMD | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 2.9% | 2.4% | 2.2% |
| 1Y | 163.0% | 16.2% | 31.7% |
Return vs Industry: RVMD exceeded the US Biotechs industry which returned 15.2% over the past year.
Return vs Market: RVMD exceeded the US Market which returned 31.1% over the past year.
Price Volatility
| RVMD volatility | |
|---|---|
| RVMD Average Weekly Movement | 5.7% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: RVMD has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: RVMD's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 490 | Mark Goldsmith | www.revmed.com |
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets.
Revolution Medicines, Inc. Fundamentals Summary
| RVMD fundamental statistics | |
|---|---|
| Market cap | US$9.55b |
| Earnings (TTM) | -US$567.06m |
| Revenue (TTM) | US$742.00k |
Over9,999x
P/S Ratio-16.8x
P/E RatioIs RVMD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RVMD income statement (TTM) | |
|---|---|
| Revenue | US$742.00k |
| Cost of Revenue | US$426.14m |
| Gross Profit | -US$425.40m |
| Other Expenses | US$141.66m |
| Earnings | -US$567.06m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.37 |
| Gross Margin | -57,331.27% |
| Net Profit Margin | -76,423.32% |
| Debt/Equity Ratio | 0% |
How did RVMD perform over the long term?
See historical performance and comparison